Silent Cerebrovascular Lesion and Cognitive Decline Prevention by Cholesterol Lowering in Elderly AF Patients
- Conditions
- Atrial FibrillationNeuropsychologyMagnetic Resonance ImagingInflammationHemostasis
- Registration Number
- NCT00449410
- Lead Sponsor
- Radboud University Medical Center
- Brief Summary
In elderly patients with atrial fibrillation (AF) the presence of silent brain infarcts and neurocognitive deficit is high despite adequate treatment with oral anticoagulation. Atherosclerosis is considered to be a chronic inflammatory disease and thrombosis and inflammation are strongly correlated. Atrial fibrillation is linked with increased levels of inflammatory markers and intensive cholesterol lowering has proven to reduce inflammation. In a prospective double-blind randomized pilot-study we want to test the hypothesis, that addition of intensive cholesterol lowering treatment besides adequate oral anticoagulation will reduce cerebrovascular lesions and will be beneficial for neurocognitive status in elderly AF patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 35
- Elderly patients (>68 and <82 years) with atrial fibrillation and adequate oral anticoagulation therapy and cholesterol levels between 4,5 mmol/l and 7 mmol/l
- Indication for cholesterol lowering treatment according to Dutch CBO-cholesterol guidelines (2004)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Neurocognitive function Cerebrovascular lesions on MRI
- Secondary Outcome Measures
Name Time Method Level of inflammatory markers Level of hemostatic markers
Trial Locations
- Locations (1)
Gheorghe AM Pop
🇳🇱Nijmegen, Netherlands